Laurens F. Reeskamp

2.3k citations

65 papers · 1.4k indexed · 2 hit papers · h-index 20

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes, Cardiovascular Risks, and Lipoproteins 11
Cardiology and Cardiovascular Medicine top 5%
- Lipid metabolism and disorders 12
Cancer Research top 5%
- Cancer, Lipids, and Metabolism 14
Surgery top 5%
- Lipoproteins and Cardiovascular Health 49
- Cholesterol and Lipid Metabolism 6
Pathology and Forensic Medicine
- Genetic factors in colorectal cancer 9
Immunology
- Atherosclerosis and Cardiovascular Diseases 6
Economics and Econometrics
- Health Systems, Economic Evaluations, Quality of Life 4

Co-authors: G. Kees Hovingh Erik S.G. Stroes John J.P. Kastelein Daniel A. Gipe Paolo Rubba Kuo‐Chen Chan Robert Pordy Frederick J. Raal
Cited by: Endocrinology, Diabetes and Metabolism Cardiology and Cardiovascular Medicine Cancer Research
Journals: New England Journal of Medicine (1 paper)Circulation (3 papers)Journal of the American College of Cardiology (2 papers)
Partner nations: Netherlands United States Italy

In The Last Decade

Laurens F. Reeskamp

63 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Laurens F. Reeskamp

Since Specialization

Citations

This map shows the geographic impact of Laurens F. Reeskamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurens F. Reeskamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurens F. Reeskamp more than expected).

Fields of papers citing papers by Laurens F. Reeskamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurens F. Reeskamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurens F. Reeskamp. The network helps show where Laurens F. Reeskamp may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Laurens F. Reeskamp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Laurens F. Reeskamp Line = papers co-authored together Laurens F. Reeskamp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk studybreakdown → European Heart Journal ·Jordan M Kraaijenhof,Nick S. Nurmohamed,Ask Tybjærg Nordestgaard,Laurens F. Reeskamp,Erik S G Stroes,G. Kees Hovingh,S. Matthijs Boekholdt,Paul M. Ridker	2025	19
2	Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia – A physician survey Journal of clinical lipidology ·Willemijn Schonck,Janneke W.C.M. Mulder,Tycho R. Tromp,Laurens F. Reeskamp,G. Kees Hovingh,Jeanine E. Roeters van Lennep,Dirk Blom	2025	2
3	Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia European Journal of Preventive Cardiology ·Shirin Ibrahim,Laurens F. Reeskamp,Jim N. de Goeij,G. Kees Hovingh,R. Nils Planken,Willem A. Bax,James K. Min,James P. Earls,Paul Knaapen,Albert Wiegman,Erik S.G. Stroes,Nick S. Nurmohamed	2024	11
4	Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover Study Journal of the American Heart Association ·Reindert F. Oostveen,Yannick Kaiser,Merel L. Hartgers,Emma C. E. Meessen,Aldo Grefhorst,G. Kees Hovingh,Folkert Kuipers,Erik S. G. Stroes,Albert K. Groen,Laurens F. Reeskamp	2024	2
5	Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature Drugs ·Willemijn Schonck,Erik S.G. Stroes,G. Kees Hovingh,Laurens F. Reeskamp	2024	17
6	LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia Atherosclerosis ·Shirin Ibrahim,Merel L. Hartgers,Laurens F. Reeskamp,Linda Zuurbier,Joep C. Defesche,John J.P. Kastelein,Erik S.G. Stroes,G. Kees Hovingh,Roeland Huijgen	2024	2
7	Enhanced identification of familial hypercholesterolemia using central laboratory algorithms Atherosclerosis ·Shirin Ibrahim,Nick S. Nurmohamed,Melchior C. Nierman,Jim N. de Goeij,Linda Zuurbier,Jeroen van Rooij,Willemijn Schonck,Jard de Vries,G. Kees Hovingh,Laurens F. Reeskamp,Erik S.G. Stroes	2024	1
8	Impact of cumulative LDL cholesterol and other risk factors on coronary artery disease prevalence in patients with familial hypercholesterolaemia European Journal of Preventive Cardiology ·Shirin Ibrahim,G. Kees Hovingh,Barbara A. Hutten,Erik S.G. Stroes,Laurens F. Reeskamp	2024	2
9	Lifetime exposure to high LDL cholesterol in familial hypercholesterolemia causes coronary atherosclerosis in young adults: The cheetah trial Atherosclerosis ·Saifeddin Ibrahim,J. De Goeij,Laurens F. Reeskamp,R. Nils Planken,G.K. Hovingh,James K. Min,James P. Earls,Paul Knaapen,Albert Wiegman,Erik S.G. Stroes,N. Nurmohamed	2023	1
10	Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia JACC Advances ·Laurens F. Reeskamp,Injeong Shim,Jacqueline S. Dron,Shirin Ibrahim,Tycho R. Tromp,Akl C. Fahed,Aniruddh P. Patel,Barbara A. Hutten,Erik S.G. Stroes,G. Kees Hovingh,Amit V. Khera	2023	7
11	Low-Cost High-Throughput Genotyping for Diagnosing Familial Hypercholesterolemia Circulation Genomic and Precision Medicine ·Shirin Ibrahim,Jeroen van Rooij,Annemieke J.M.H. Verkerk,Jard de Vries,Linda Zuurbier,Joep C. Defesche,Jorge Peter,Willemijn Schonck,Bahareh Sedaghati-khayat,G. Kees Hovingh,André G. Uitterlinden,Erik S.G. Stroes,Laurens F. Reeskamp	2023	3
12	The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia JACC Advances ·Frederick J. Raal,Robert S. Rosenson,Laurens F. Reeskamp,John J.P. Kastelein,Paolo Rubba,P. Barton Duell,Masahiro Koseki,Erik S.G. Stroes,Shazia Ali,Poulabi Banerjee,Kuo‐Chen Chan,Nagwa Khilla,Jennifer McGinniss,Robert Pordy,Yi Zhang,Daniel Gaudet	2023	15
13	ANGPTL3 (Angiopoietin‐Like 3) Preferentially Resides on High‐Density Lipoprotein in the Human Circulation, Affecting Its Activity Journal of the American Heart Association ·Jordan M Kraaijenhof,Tycho R. Tromp,Nick S. Nurmohamed,Laurens F. Reeskamp,Marije Langenkamp,J.H.M. Levels,S. Matthijs Boekholdt,Nicholas J. Wareham,Menno Hoekstra,Erik S.G. Stroes,G. Kees Hovingh,Aldo Grefhorst	2023	5
14	Association Between Self‐Rated Medication Adherence and Adverse Cardiovascular Outcomes in Patients With Hypertension Journal of the American Heart Association ·Shirin Ibrahim,Nick S. Nurmohamed,Didier Collard,Anouk de Weger,G. Kees Hovingh,Bert‐Jan H. van den Born,Laurens F. Reeskamp,Erik S.G. Stroes,Tom F. Brouwer	2023	4
15	Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia Atherosclerosis ·Tycho R. Tromp,Shirin Ibrahim,Nick S. Nurmohamed,Jorge Peter,Linda Zuurbier,Joep C. Defesche,Laurens F. Reeskamp,G. Kees Hovingh,Erik S.G. Stroes	2022	8
16	Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study BMJ Open ·Didier Collard,Nick S. Nurmohamed,Yannick Kaiser,Laurens F. Reeskamp,Tom Dormans,Hazra S. Moeniralam,Suat Şimşek,Renée Douma,Annet Eerens,Auke C. Reidinga,Paul Elbers,Martijn Beudel,Liffert Vogt,Erik S.G. Stroes,Bert‐Jan H. van den Born	2021	28
17	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report Arteriosclerosis Thrombosis and Vascular Biology ·Laurens F. Reeskamp,John S. Millar,WU Li-ya,Hans Jansen,Dewi van Harskamp,Henk Schierbeek,Daniel A. Gipe,Daniel J. Rader,Geesje M. Dallinga‐Thie,G. Kees Hovingh,Marina Cuchel	2021	67
18	Marked plaque regression in homozygous familial hypercholesterolemia Atherosclerosis ·Laurens F. Reeskamp,Nick S. Nurmohamed,Michiel J. Bom,R. Nils Planken,Roel S. Driessen,Pepijn A. van Diemen,Ilse K. Luirink,Jaap W. Groothoff,Irene M. Kuipers,Paul Knaapen,Erik S.G. Stroes,Albert Wiegman,G. Kees Hovingh	2021	44
19	Combination lipid-lowering therapy as first-line strategy in very high-risk patients European Heart Journal ·Kausik K. Ray,Laurens F. Reeskamp,Ulrich Laufs,Maciej Banach,François Mach,Lâle Tokgözoğlu,Derek Connolly,Anja J. Gerrits,Erik S.G. Stroes,L. Masana,John J.P. Kastelein	2021	123
20	Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation Atherosclerosis ·Laurens F. Reeskamp,Tycho R. Tromp,Roeland Huijgen,Erik S.G. Stroes,G. Kees Hovingh,Aldo Grefhorst	2020	8

About Laurens F. Reeskamp

Laurens F. Reeskamp is a scholar working on Surgery, Cancer Research and Family Practice, having authored 65 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (49 papers), Cancer, Lipids, and Metabolism (14 papers), Lipid metabolism and disorders (12 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers), Genetic factors in colorectal cancer (9 papers), Atherosclerosis and Cardiovascular Diseases (6 papers), Cholesterol and Lipid Metabolism (6 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (416 citations), Cardiology and Cardiovascular Medicine (531 citations) and Cancer Research (335 citations). Laurens F. Reeskamp has collaborated with scholars based in Netherlands, United States and Italy. Frequent co-authors include G. Kees Hovingh, Erik S.G. Stroes, John J.P. Kastelein, Daniel A. Gipe, Paolo Rubba, Kuo‐Chen Chan, Robert Pordy, Frederick J. Raal, Shazia Ali and Daniel Gaudet. Their work appears in journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact